REACT and ITOG Merger, December 2018

The Board of Directors would like to thank you for supporting REACT, the inspiration of my dear daughter Michelle. Her passion and initiative to help others afflicted with medullary thyroid carcinoma (MTC) by creating REACT exemplifies her heart and selflessness.

Since Michelle’s passing, my daughter Kimberly and I have done our best to continue the good work of REACT, along with the wonderful assistance of many volunteers. We have raised over $750,000 over the years to invest in research to find a cure for thyroid cancer.

Kimberly and I have decided that the best way to keep Michelle’s legacy alive and expand the great work of REACT is to merge with the International Thyroid Oncology Group, or ITOG. ITOG is the preeminent organization that brings together the leaders in the field to develop better treatments for all types of thyroid cancer, including MTC. ITOG was inspired by another MTC patient, who like Michelle, turned her anxiety and feelings of hopelessness into action. The merger with ITOG should be effective January 1, 2019.

The REACT name and mission will be preserved with ITOG. You can continue to support the work of REACT through your existing mechanisms. You will also see greater involvement from our friends at ITOG.

Kimberly and I are confident that ITOG has the best team to nurture and execute the mission of REACT. I know Michelle would be pleased as well.